HK Stock Market Move | BEIGENE (06160) rises more than 5%. BeiGene was previously approved for a new indication in the United States. The company's pipeline of oncology products is further expanding.

BEIGENE (06160) rose over 5%, reaching a 5.16% increase at the time of writing, trading at 110 Hong Kong dollars with a turnover of 1.47 billion Hong Kong dollars. In terms of news, BEIGENE previously announced that the US Food and Drug Administration (FDA) has approved the use of Bemarituzumab (antibody) in combination with platinum and fluorouracil chemotherapy for the first-line treatment of adult patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (1). The new indication is based on the results of a global Phase 3 trial, which demonstrated that Bemarituzumab in combination with chemotherapy significantly improves the overall survival of patients with advanced gastric cancer. This is the second approval granted to Bemarituzumab by the FDA in 2024. BEIGENE previously released its financial performance and research pipeline progress for the third quarter of 2024. The company's key research projects in hematology are progressing rapidly, while its pipeline of oncology products is also expanding. Data shows that in the third quarter, BEIGENE had 4 new molecular entities (NME) entering clinical development stage (a total of 8 since the beginning of 2024), and is expected to exceed the goal of having more than 10 NMEs enter clinical trials for the year.